Navigation Links
Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board
Date:7/27/2009

CAMBRIDGE, Mass., July 27 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced that David Julius, PhD, professor and chair of the department of physiology at the University of California, San Francisco, and a leading pioneer in the pathophysiology of pain, has joined Solace's scientific advisory board.

"We admire Professor Julius' pioneering research in the biology of pain and welcome his participation on Solace's scientific advisory board," said Dr. Eliot Forster, Solace's Chief Executive Officer. "We believe that Professor Julius' scientific interests are complementary to those of Solace, especially with respect to his recent work in glial cells, and we share his dedication to transforming biological insights into opportunities for drug discovery and development. We believe that Professor Julius' expertise will enrich our world-class scientific advisory board and we are pleased to have him join in our mission to discover and develop innovative treatments for pain."

Professor Julius comments, "Solace has staked out some very innovative approaches for targeting and tackling chronic pain. I look forward to working with an extraordinarily talented and diverse group of advisors to bring new ideas to the treatment of pain based on knowledge of its underlying mechanisms."

Professor Julius has made significant discoveries in the molecular basis of somatosensation - the process whereby we experience touch and temperature - and how somatosensation is altered in response to tissue or nerve injury. Professor Julius discovered that capsaicin, the main pungent ingredient in chili peppers, activates an excitatory ion channel, called TRPV1, on sensory nerve endings, and that TRPV1 functions as a molecular integrator of physical and chemical signals that regulate sensory neuron excitability under both normal and pathophysiological conditions. Following a similar paradigm, Professor Julius' research showed that a menthol receptor from primary sensory neurons is activated by cold thermal stimuli, and that the structure of this menthol/cold receptor, TRPM8, resembles that of TRPV1.

Professor Julius has received considerable recognition during his career. He has twice received awards from The McKnight Endowment Fund for Neuroscience, and in 2007, he was awarded the Edward M. Scolnick Prize in Neuroscience from The McGovern Institute for Brain Research at the Massachusetts Institute of Technology. Professor Julius has published widely in Nature, Cell, Science, and other prestigious publications. He earned his bachelor's degree at the Massachusetts Institute of Technology and his Ph.D. at the University of California, Berkeley. He is a member of the National Academy of Sciences.

About Solace Pharmaceuticals

Solace Pharmaceuticals discovers and develops innovative treatments for pain. Solace's research and development programs are focused on exploiting novel biological understanding of disease targets that play a role in the pathogenesis of pain and that have disease-modifying potential in two key areas: modulating the activity of glial cells and intervening in the tetrohydrobiopterin (BH4) pathway. SLC022, the company's lead drug candidate, is in phase II clinical development in patients with post-herpetic neuralgia (PHN). Solace's research and development are supported by a strong and expanding intellectual property portfolio. For more information, please visit the company's website at www.solacepharma.com.

    Contact:

    Marie Lossky, PhD
    Director, Business Development and
    Intellectual Property
    Solace Pharmaceuticals
    Phone: 617 401 4006
    Email: mlossky@solacepharma.com


'/>"/>
SOURCE Solace Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
2. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
3. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
4. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
5. NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region
6. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
7. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
8. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
10. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
11. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer ... hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. ... development activities. , “Dr. Floyd’s career has spanned 30 years in the chemicals ...
(Date:3/22/2017)... March 22, 2017  UBM and the Massachusetts ... their extended partnership and the third annual Massachusetts Medtech ... the 21 st Annual MassMEDIC Conference held ... May 3-4, 2017. MassMEDIC will ... (ADVAMED) President and CEO, Scott Whitaker , ...
(Date:3/22/2017)... March 22, 2017 The global ... a research report by Transparency Market Research (TMR). The ... Inc., and AbbVie Inc., accounted for a share of ... players in this market are focusing aggressively on mergers, ... which is likely to lead to market consolidation in ...
(Date:3/22/2017)... , March 22, 2017   ... independent provider of product and service solutions ... that it has acquired EPL Archives, Inc., ... customers across the entire regulated product research, ... sample, document storage and ancillary services. EPL ...
Breaking Biology Technology:
(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 ... Senate Judiciary Committee, Janice Kephart of Identity ... President Donald Trump,s "Executive Order: Protecting the ... (Jan. 27, 2017):  "As President Trump,s ,Travel ... Circuit has now essentially banned the travel ban, it ...
Breaking Biology News(10 mins):